Treatment of panic disorder in older adults: A pilot study comparison of alprazolam, imipramine, and placebo

Javaid Sheikh, Pamela J. Swales

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Objective: Several studies have documented that a variety of pharmacological compounds are quite effective in controlling acute symptomatology of panic disorder in the general population. However, there is a paucity of such studies in the management of panic disorder in older adults (ages 55 and above). The purpose of this study was to gather pilot data in older patients with panic disorder to begin to assess the efficacy of two commonly-used antipanic medications, imipramine and alprazolam. Method: Twenty-five (n = 25 (23 females; 2 males); 18 completers, 7 dropouts) older panic disorder (DSM-III-R) patients (age range = 55-73; mean = 61.24) were studied in an eight-week randomized, parallel-groups, double-blind, placebo- controlled, flexible dose design. Outcome was assessed weekly by global change ratings (Hamilton Anxiety and Depression Scales; Physicians' Global Impression ratings) and panic diaries. Because of small sample size, we present data descriptively. Results: Subjects in active medication groups evidenced reductions in panic attacks and in levels of overall anxiety and depression. Therapeutic dosages were approximately half those commonly used in younger panic disorder patients. Conclusion: Our data suggest the comparable efficacy of alprazolam and imipramine in the short-term treatment of older adults with panic disorder. There is clearly the need for a larger scale placebo-controlled study, preferably comparing imipramine and/or alprazolam with one of the SSRIs, to substantiate our findings.

Original languageEnglish
Pages (from-to)107-117
Number of pages11
JournalInternational Journal of Psychiatry in Medicine
Volume29
Issue number1
DOIs
Publication statusPublished - 1999
Externally publishedYes

Fingerprint

Alprazolam
Imipramine
Panic Disorder
Placebos
Therapeutics
Anxiety
Depression
Panic
Diagnostic and Statistical Manual of Mental Disorders
Sample Size
Pharmacology
Physicians

Keywords

  • Alprazolam and imipramine
  • Older adults
  • Panic disorder

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Treatment of panic disorder in older adults : A pilot study comparison of alprazolam, imipramine, and placebo. / Sheikh, Javaid; Swales, Pamela J.

In: International Journal of Psychiatry in Medicine, Vol. 29, No. 1, 1999, p. 107-117.

Research output: Contribution to journalArticle

@article{a99d0c611f2848808a1906349e8edf36,
title = "Treatment of panic disorder in older adults: A pilot study comparison of alprazolam, imipramine, and placebo",
abstract = "Objective: Several studies have documented that a variety of pharmacological compounds are quite effective in controlling acute symptomatology of panic disorder in the general population. However, there is a paucity of such studies in the management of panic disorder in older adults (ages 55 and above). The purpose of this study was to gather pilot data in older patients with panic disorder to begin to assess the efficacy of two commonly-used antipanic medications, imipramine and alprazolam. Method: Twenty-five (n = 25 (23 females; 2 males); 18 completers, 7 dropouts) older panic disorder (DSM-III-R) patients (age range = 55-73; mean = 61.24) were studied in an eight-week randomized, parallel-groups, double-blind, placebo- controlled, flexible dose design. Outcome was assessed weekly by global change ratings (Hamilton Anxiety and Depression Scales; Physicians' Global Impression ratings) and panic diaries. Because of small sample size, we present data descriptively. Results: Subjects in active medication groups evidenced reductions in panic attacks and in levels of overall anxiety and depression. Therapeutic dosages were approximately half those commonly used in younger panic disorder patients. Conclusion: Our data suggest the comparable efficacy of alprazolam and imipramine in the short-term treatment of older adults with panic disorder. There is clearly the need for a larger scale placebo-controlled study, preferably comparing imipramine and/or alprazolam with one of the SSRIs, to substantiate our findings.",
keywords = "Alprazolam and imipramine, Older adults, Panic disorder",
author = "Javaid Sheikh and Swales, {Pamela J.}",
year = "1999",
doi = "10.2190/KQEJ-MQJR-VK3D-F3HV",
language = "English",
volume = "29",
pages = "107--117",
journal = "International Journal of Psychiatry in Medicine",
issn = "0091-2174",
publisher = "Baywood Publishing Co. Inc.",
number = "1",

}

TY - JOUR

T1 - Treatment of panic disorder in older adults

T2 - A pilot study comparison of alprazolam, imipramine, and placebo

AU - Sheikh, Javaid

AU - Swales, Pamela J.

PY - 1999

Y1 - 1999

N2 - Objective: Several studies have documented that a variety of pharmacological compounds are quite effective in controlling acute symptomatology of panic disorder in the general population. However, there is a paucity of such studies in the management of panic disorder in older adults (ages 55 and above). The purpose of this study was to gather pilot data in older patients with panic disorder to begin to assess the efficacy of two commonly-used antipanic medications, imipramine and alprazolam. Method: Twenty-five (n = 25 (23 females; 2 males); 18 completers, 7 dropouts) older panic disorder (DSM-III-R) patients (age range = 55-73; mean = 61.24) were studied in an eight-week randomized, parallel-groups, double-blind, placebo- controlled, flexible dose design. Outcome was assessed weekly by global change ratings (Hamilton Anxiety and Depression Scales; Physicians' Global Impression ratings) and panic diaries. Because of small sample size, we present data descriptively. Results: Subjects in active medication groups evidenced reductions in panic attacks and in levels of overall anxiety and depression. Therapeutic dosages were approximately half those commonly used in younger panic disorder patients. Conclusion: Our data suggest the comparable efficacy of alprazolam and imipramine in the short-term treatment of older adults with panic disorder. There is clearly the need for a larger scale placebo-controlled study, preferably comparing imipramine and/or alprazolam with one of the SSRIs, to substantiate our findings.

AB - Objective: Several studies have documented that a variety of pharmacological compounds are quite effective in controlling acute symptomatology of panic disorder in the general population. However, there is a paucity of such studies in the management of panic disorder in older adults (ages 55 and above). The purpose of this study was to gather pilot data in older patients with panic disorder to begin to assess the efficacy of two commonly-used antipanic medications, imipramine and alprazolam. Method: Twenty-five (n = 25 (23 females; 2 males); 18 completers, 7 dropouts) older panic disorder (DSM-III-R) patients (age range = 55-73; mean = 61.24) were studied in an eight-week randomized, parallel-groups, double-blind, placebo- controlled, flexible dose design. Outcome was assessed weekly by global change ratings (Hamilton Anxiety and Depression Scales; Physicians' Global Impression ratings) and panic diaries. Because of small sample size, we present data descriptively. Results: Subjects in active medication groups evidenced reductions in panic attacks and in levels of overall anxiety and depression. Therapeutic dosages were approximately half those commonly used in younger panic disorder patients. Conclusion: Our data suggest the comparable efficacy of alprazolam and imipramine in the short-term treatment of older adults with panic disorder. There is clearly the need for a larger scale placebo-controlled study, preferably comparing imipramine and/or alprazolam with one of the SSRIs, to substantiate our findings.

KW - Alprazolam and imipramine

KW - Older adults

KW - Panic disorder

UR - http://www.scopus.com/inward/record.url?scp=0032967567&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032967567&partnerID=8YFLogxK

U2 - 10.2190/KQEJ-MQJR-VK3D-F3HV

DO - 10.2190/KQEJ-MQJR-VK3D-F3HV

M3 - Article

C2 - 10376237

AN - SCOPUS:0032967567

VL - 29

SP - 107

EP - 117

JO - International Journal of Psychiatry in Medicine

JF - International Journal of Psychiatry in Medicine

SN - 0091-2174

IS - 1

ER -